GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arrowhead Pharmaceuticals Inc (STU:HDP1) » Definitions » Shares Outstanding (EOP)

Arrowhead Pharmaceuticals (STU:HDP1) Shares Outstanding (EOP) : 107.5 Mil (As of Dec. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Arrowhead Pharmaceuticals Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Arrowhead Pharmaceuticals's shares outstanding for the quarter that ended in Dec. 2023 was 107.5 Mil.

Arrowhead Pharmaceuticals's quarterly shares outstanding increased from Sep. 2023 (107.3 Mil) to Dec. 2023 (107.5 Mil). It means Arrowhead Pharmaceuticals issued new shares from Sep. 2023 to Dec. 2023 .

Arrowhead Pharmaceuticals's annual shares outstanding increased from Sep. 2022 (106.0 Mil) to Sep. 2023 (107.3 Mil). It means Arrowhead Pharmaceuticals issued new shares from Sep. 2022 to Sep. 2023 .


Arrowhead Pharmaceuticals Shares Outstanding (EOP) Historical Data

The historical data trend for Arrowhead Pharmaceuticals's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arrowhead Pharmaceuticals Shares Outstanding (EOP) Chart

Arrowhead Pharmaceuticals Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 95.51 102.38 104.33 105.96 107.31

Arrowhead Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 106.14 106.87 107.10 107.31 107.50

Competitive Comparison of Arrowhead Pharmaceuticals's Shares Outstanding (EOP)

For the Biotechnology subindustry, Arrowhead Pharmaceuticals's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arrowhead Pharmaceuticals's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arrowhead Pharmaceuticals's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Arrowhead Pharmaceuticals's Shares Outstanding (EOP) falls into.



Arrowhead Pharmaceuticals Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Arrowhead Pharmaceuticals  (STU:HDP1) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Arrowhead Pharmaceuticals Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Arrowhead Pharmaceuticals's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Arrowhead Pharmaceuticals (STU:HDP1) Business Description

Traded in Other Exchanges
Address
177 E. Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Arrowhead Pharmaceuticals (STU:HDP1) Headlines

No Headlines